30-year Gilead R&D vet Nor­bert Bischof­berg­er is start­ing over as staffer #5 at an up­start biotech — and he’s lov­ing it

Af­ter spend­ing the past 30 years be­fore the R&D mast at Gilead, ex-re­search chief Nor­bert Bischof­berg­er is start­ing over from scratch. 

This morn­ing, just a few weeks af­ter his for­mal de­par­ture from the head job at one of the world’s top 15 drug re­search or­ga­ni­za­tions, Bischof­berg­er is jump­ing on board at an up­start biotech with just 4 full time staffers. 

An­gela Koehler

He’s chipped in to an $18 mil­lion seed round — rough­ly 1/200th the size of this year’s R&D bud­get at Gilead — to launch Kro­nos Bio. The biotech in-li­censed a plat­form tech­nol­o­gy out of the lab of MIT pro­fes­sor An­gela Koehler fo­cused on mod­u­lat­ing tran­scrip­tion fac­tors in can­cer,  with two pre­clin­i­cal pro­grams fo­cused on MYC and the red hot an­dro­gen re­cep­tor tar­get. And they’re tak­ing a shot at break­ing new ground in can­cer R&D.

This isn’t a spur of the mo­ment de­ci­sion, Bischof­berg­er tells me. He start­ed ac­tive­ly hunt­ing around for a new biotech start­up idea in Jan­u­ary. And when Kite founder, biotech en­tre­pre­neur and ven­ture in­vestor Arie Bellde­grun was talk­ing over his plans for Kro­nos with Gilead chair­man John Mar­tin, Mar­tin point­ed him in Bischof­berg­er’s di­rec­tion, know­ing that he had be­gun to hunt for the right start­up.

“I want­ed to start my own com­pa­ny,” says Bischof­berg­er, “but it was a very vague idea, think­ing about AI and health­care.” In Jan­u­ary, he at­tend­ed a con­fer­ence on AI to ex­plore it more and came to the re­al­iza­tion that “every­body and their moth­er is do­ing AI. Then along came Arie.”

Arie Bellde­grun

With his back­ground and these kinds of con­nec­tions, Bischof­berg­er could just as eas­i­ly have raised $100 mil­lion-plus. But he’s in­tent on tak­ing a mea­sured ap­proach ear­ly on, hap­py to have in­vest­ed a chunk of his own mon­ey in the start­up to re­serve sub­stan­tial eq­ui­ty. And in ad­di­tion to the FTEs on board, em­ploy­ee #5 at Kro­nos al­so can tap 15 to 20 staffers un­der con­tract in In­dia.

Ex­cit­ed much?

 “I want to do it again,” says a cheer­ful Bischof­berg­er, “I’m 62, I feel like 42 and be­have like I’m 22… I’ve done it and seen it all, now I want to ap­ply it to my own ideas.”

John Mar­tin

Bischof­berg­er’s de­par­ture may have been a sur­prise to many, but these days ex­pe­ri­enced bio­phar­ma ex­ecs can prac­ti­cal­ly write their own tick­ets in biotech. George Scan­gos left Bio­gen to start Vir and David Meek­er left the helm at Gen­zyme to launch KSQ. Bellde­grun him­self went from the $12 bil­lion sale of Kite to Gilead straight in­to a start­up of his own, com­plete with an am­bi­tious li­cens­ing pact in place with Pfiz­er. An ex­o­dus of Big Phar­ma ex­ecs, mean­while, is pop­u­lat­ing the start­up world, in­ter­est­ed in grow­ing big new com­pa­nies on the back of promis­ing new tech­nolo­gies.

Why do it? In Bischof­berg­er’s view, it’s a chance to drop the myr­i­ad de­mands of a large or­ga­ni­za­tion, dom­i­nat­ed by HR is­sues and more, and get back in­to fo­cused drug de­vel­op­ment work.

Re­bec­ka Bellde­grun

Bischof­berg­er plans to stay on the West Coast, even though Kro­nos is in Cam­bridge, MA, and will be grow­ing the staff on the East Coast hub. But he counts his flight time as one of his most pro­duc­tive times, able to sep­a­rate from his sur­round­ings and con­cen­trate on the men­tal tasks at hand. So he doesn’t see com­mut­ing as a waste of time.

John Mar­tin likes it all. He vol­un­teered to jump in on the seed round for the Two Rivers port­fo­lio com­pa­ny. Oth­er in­vestors in­clude Omega Funds, Bell­Co Cap­i­tal and Vi­da Ven­tures, LLC. As part of the fi­nanc­ing Bischof­berg­er and Mar­tin, as well as Re­bec­ka Bellde­grun — physi­cian and wife of Kite founder Arie Belde­grun — and Otel­lo Stam­pac­chia joined the com­pa­ny’s board of di­rec­tors.


Im­age: Nor­bert Bischof­berg­er. KRO­NOS

Un­lock­ing ESG strate­gies for growth with Gilead Sci­ences

RBC Capital Markets explores what is material in ESG for biopharma companies with the ESG leads at Gilead Sciences. Gilead has long focused on sustainability but recognized a more robust framework was needed. Based on a materiality assessment, Gilead’s ESG strategy today focuses first on drug access and pricing, while also addressing D&I and climate change. Find out why Gilead’s board is “acutely aware” of the contribution that ESG makes to firm’s overall success.

What con­tro­ver­sy? Eli Lil­ly plots Alzheimer's BLA fil­ing lat­er this year as FDA taps more an­ti-amy­loid drugs as break­throughs

The FDA is keeping the good news coming for Alzheimer’s drug developers. And Eli Lilly is taking them up on it.

Amid continued controversy around whether Biogen’s new flagship drug, Aduhelm, should have been approved at all — and swelling, heated debates surrounding its $56,000 price tag — the agency had no issue handing them and their Japanese partner Eisai a breakthrough therapy designation for a second anti-amyloid beta antibody, lecanemab, late Wednesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

Karen Flynn, Catalent

Q&A: When the pan­dem­ic struck, Catal­en­t's CCO had just joined the team

Karen Flynn came aboard Catalent’s team just in time.

The company was going through a surge of changes, and she had been brought over from her role as CCO of West Pharmaceutical Services to serve in the same capacity for the New Jersey-based CDMO. Then a few months later, the pandemic was in full-force.

Since then, Catalent’s been in hyper-expansion mode. In early May, it acquired Promethera’s Hepatic Cell Therapy Support SA subsidiary and its 32,40-square-foot facility in Gosselies, Belgium. Prior to that, the company acquired Belgian CDMO Delphi Genetics, wrapped up the expansion of an already-existing site in Madison, WI and added an ultra-low temperature freezer partner in Sterling. As Emergent has botched millions of doses of AstraZeneca’s vaccine, the company has swooped in to move that production to its Maryland plant as well.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

James Peyer, Cambrian

Can a cell ther­a­py treat mus­cu­lar dy­s­tro­phy? A Ger­man bil­lion­aire's an­ti-ag­ing start­up is try­ing to find out

Gene therapy companies have faced huge hurdles trying to deliver healthy genes into muscular dystrophy patients’ muscle cells, so here’s an idea: Why don’t we just replace the muscle cells themselves?

Over the last two years, Vita Therapeutics has been exploring that possibility, building on early stem cell work from Johns Hopkins professor Peter Andersen. And on Tuesday they announced a $32 million Series A to begin to move their first therapy into the clinic, where they hope it will help rebuild muscle in patients with a type of dystrophy that afflicts the arms and legs.

Hervé Hoppenot, Incyte CEO (Jeff Rumans)

ODAC echoes FDA con­cern over In­cyte PD-1, as Paz­dur sig­nals broad­er shift for ac­cel­er­at­ed ap­proval

After the FDA lambasted their PD-1 ahead of an adcomm earlier this week, Incyte ran into new trouble Thursday as ODAC panelists voted against an accelerated OK by a wide margin.

Members of the Oncologic Drugs Advisory Committee recommended with a 13-4 vote to defer a regulatory decision on Incyte’s retifanlimab until after more data can be collected from a placebo-controlled trial. The PD-1 therapy is due for a PDUFA date in late July after receiving priority review earlier this year.

New FDA doc­u­ments show in­ter­nal dis­sent on Aduhelm ap­proval

In a lengthy review document and a pair of memos from top officials, the FDA released on Tuesday night its most detailed argument yet for approving Biogen’s intensely controversial Alzheimer’s drug aducanumab.

The documents amount to an agency attempt to quench the firestorm their decision kindled, as outside advisors members resigned and experts warned that an unproven drug now could stretch Medicare’s budget to a breaking point. Ultimately, the documents show how CDER director Patrizia Cavazzoni and Office of New Drugs director Peter Stein both concurred with FDA neuroscience head Billy Dunn on the accelerated approval while the staff at FDA’s Office of Biostatistics did not think an approval was warranted.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

Richard Pazdur (vis AACR)

FDA en­cour­ages in­clud­ing in­cur­able can­cer pa­tients in tri­als, re­gard­less of pri­or ther­a­pies

The FDA on Thursday called to include those with incurable cancers (when there is no potential for cure or for prolonged/near normal survival) in appropriate clinical trials, regardless of whether they have received existing alternative treatments.

Historically, many cancer clinical trials have required that participating patients previously received multiple therapies, according to Richard Pazdur, director of the FDA’s Oncology Center of Excellence.

On heels of Aduhelm ap­proval, Bris­tol My­ers jumps back in­to Alzheimer's race

Bristol Myers Squibb last put major resources behind an Alzheimer’s drug nearly a decade ago, when their own attempt at targeting amyloid flamed out in mid-stage studies. They invented another molecule, a Tau-targeted antibody, but jettisoned it to Biogen in 2017 as they dropped out of neuroscience altogether.

But on Thursday, the New York pharma announced they were getting back in the game. Bristol Myers exercised an $80 million option to bring a tau-targeted antibody from Prothena into a Phase I study. The opt-in, which Bristol Myers triggered ahead of analyst expectations, opens the door for another $1.7 billion in milestones down the road.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

Alexis Borisy (file photo)

EQRx and Ex­sci­en­tia, a pair of self-styled dis­rup­tors, team up to over­turn the drug pric­ing ap­ple cart

The biotech industry has seen no shortage of innovation in recent years, but in one area — drug pricing — the field has been anything but innovative. Now, two brash startups taking different roads to upset the drug pricing model will partner up to create a sort of “super-disruptor.”

EQRx and UK-based AI specialist Exscientia will team up on a discovery-through-commercialization collaboration the partners hope will work better than the sum of its parts to bring cheaper medicines to patients faster, the companies said Thursday.